Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance

Published:2017-06-15 Issue:12 Volume:57 Page:1554-1563
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Adeagbo Babatunde Ayodeji¹^ORCID,Olugbade Tiwalade Adewale¹,Durosinmi Muheez Alani²,Bolarinwa Rahman Ayodele²,Ogungbenro Kayode³,Bolaji Oluseye Oladotun¹

Affiliation:

1. Department of Pharmaceutical Chemistry; Obafemi Awolowo University; Ile-Ife Nigeria

2. Department of Hematology & Immunology; Obafemi Awolowo University; Ile-Ife Nigeria

3. Cancer Pharmacometrics, Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences; University of Manchester; UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference25 articles.

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N Engl J Med,2001

2. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

3. The use of imatinib mesylate in Nigerians with chronic myeloid leukemia;Durosinmi;Cell Ther Transplant,2008

4. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example;Li-Wan-Po;Eur J Clin Pharmacol,2010

5. Metabolism and disposition of imatinib mesylate in healthy volunteers;Gschwind;Drug Metab Dispos,2005

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities;Drug Metabolism and Disposition;2024-01-29

2. Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration–Time Curve of Imatinib Mesylate in Palestinian Patients with Chronic Myeloid Leukemia;European Journal of Drug Metabolism and Pharmacokinetics;2023-11-25

3. The paucity of epidemiological data and challenges of diagnosis in myeloid neoplasms in sub‐Saharan Africa: A call for action?;Tropical Medicine & International Health;2023-11-07

4. Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation;Cancer Chemotherapy and Pharmacology;2023-08-25

5. Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies;Hematology;2023-04-20